AstraZeneca announced on Monday that the European Medicines Agency (EMA) had validated its marketing authorization application for the evaluation of Dato-DXd in two types of cancer.

The first decision concerns the treatment of locally advanced or metastatic non-squamous non-small cell cancer requiring systemic therapy after previous treatment.

The other concerns HR-positive, but HER2-negative, non-operable or metastatic breast cancer in patients whose disease has progressed and who cannot benefit from endocrine therapy following initial systemic therapy.

Datopotamab deruxtecan - or Dato-DXd - is an antibody-drug conjugate developed in collaboration with Japan's Daiichi Sankyo.

Copyright (c) 2024 CercleFinance.com. All rights reserved.